The role of interleukin-8 and its receptors in gliomagenesis and tumoral
angiogenesis

Brat, Daniel J.; Bellail, Anita C.; Meir, Erwin G. Van

doi:10.1215/s1152851704001061

Cited by 649 publications

(537 citation statements)

References 91 publications

(104 reference statements)

Supporting

Mentioning

504

Contrasting

Unclassified

Order By: Relevance

“…The relevance of CXCL8 in glioblastoma has been reported in several studies: CXCL8 is expressed and secreted at high levels both in vitro and in vivo, and it is critical for glial tumor neovascularity and progression (33). Moreover, the levels of CXCL8 correlate with histologic grade in glial neoplasms.…”

Section: Discussionmentioning

confidence: 93%

Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression

Giorgini

Trisciuoglio

Gabellini

et al. 2007

Molecular Cancer Research

View full text Add to dashboard Cite

In this paper, we investigated whether bcl-xL can be involved in the modulation of the angiogenic phenotype of human tumor cells. Using the ADF human glioblastoma and the M14 melanoma lines, and their derivative bcl-xL -overexpressing clones, we showed that the conditioned medium of bcl-xL transfectants increased in vitro endothelial cell functions, such as proliferation and morphogenesis, and in vivo vessel formation in Matrigel plugs, compared with the conditioned medium of control cells. Moreover, the overexpression of bcl-xL induced an increased expression of the proangiogenic interleukin-8 (CXCL8), both at the protein and mRNA levels, and an enhanced CXCL8 promoter activity. The role of CXCL8 on bcl-xL -induced angiogenesis was validated using CXCL8-neutralizing antibodies, whereas down-regulation of bcl-xL through antisense oligonucleotide or RNA interference strategies confirmed the involvement of bcl-xL on CXCL8 expression. Transient overexpression of bcl-xL led to extend this observation to other tumor cell lines with different origin, such as colon and prostate carcinoma. In conclusion, our results showed that CXCL8 modulation by bcl-xL regulates tumor angiogenesis, and they point to elucidate an additional function of bcl-xL protein. (Mol Cancer Res 2007;5(8):761 -71)

show abstract

Section: Discussionmentioning

confidence: 93%

Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression

Giorgini

Trisciuoglio

Gabellini

et al. 2007

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…In addition, negative correlations between vaccine-induced changes in exosomal mRNA expression levels for TIMP-1 with changes in IL-8 and TGF-b gene expression could be taken as further evidence that exosome content informs about ongoing cellular responses, whether they take place in the tumor or immune cells after vaccination. [30][31][32][33] Although these data are sparse, they indicate the potential of exosomal mRNA and protein cargos for monitoring responses to glioma immunotherapy. It is likely that using proteomics in place of total protein levels and/or a broader panel of genes for mRNA analyses in tumor-derived vs. immune cell-derived exosomes and a longer follow-up post-therapy period, exosomes might prove to be an excellent metric for measuring response to glioma therapy as also suggested by Shao et al 21 Among the three glioma patients with longest survival, patient #15 stood out because of the unique exosomal mRNA profile which was enriched in PD-1 and an inverse relationship between total exosomal protein and tumor shrinkage.…”

Section: E1008347-4mentioning

confidence: 99%

Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival

et al. 2015

View full text Add to dashboard Cite

Exosomes in plasma of glioma patients hold promise as biomarkers of prognosis. We aimed to determine whether changes in total exosomal protein and mRNA expression levels could serve as surrogate markers of immunological and clinical responses in glioma patients receiving antitumor vaccines. Exosomes were isolated from pre/post-vaccine plasma specimens in 20/22 patients enrolled in a phase I/II trial with the antitumor vaccine. Exosomal protein content was analyzed and mRNA expression levels for 24 genes were simultaneously assessed by qRT-PCR. Pre-to postvaccination changes in exosomal protein and DCt values were correlated with immunological and clinical responses and survival using Spearman rank statistics and hazard ratios (HR). Exosomal protein levels positively correlated (p < 0.0043) with the WHO tumor grade at diagnosis. Protein levels were lower in post-vs. pre-vaccination exosome fractions. Post-therapy increases in tumor size were associated with elevations in exosome proteins in glioblastoma but not always in anaplastic astrocytoma (AA). Only exosomal DCt values for IL-8, TIMP-1, TGF-b and ZAP70 were significant (p < 0.04 to p < 0.001). The DCt for IL-8 and TGF-b mRNA positively correlated with post-vaccine immunologic responses to glioma antigens, while DCt for TIMP-1 mRNA was negatively correlated to DCt for IL-8 and TGF-b. Only DCt for IL-8 weakly correlated with OS and time to progression (TTP). In post-vaccine exosomes of the longest surviving patient with AA, mRNA for PD-1 was persistently elevated. Protein and mRNA expression levels for immune-related genes in plasma exosomes were useful in evaluating glioma patients' response to vaccination therapy.

show abstract

“…Studies indicate that myeloma cells and BM stromal cells [94,95] directly produce IL-8, and elevated BM levels of IL-8 have been demonstrated in MM patients [95]. Tumor cell expression of IL-8 has been linked to the metastatic potential of many solid tumors [96,97]. In myeloma cells, IL-8 expression has also been correlated with aberrant CD28 expression and consequently with MM progression and extra-medullary localization [98].…”

Section: Matrix Metalloproteinasesmentioning

confidence: 99%

Angiogenesis and Multiple Myeloma

Giuliani

Storti

Bolzoni

et al. 2011

Cancer Microenvironment

View full text Add to dashboard Cite

The bone marrow microenvironment in multiple myeloma is characterized by an increased microvessel density. The production of pro-angiogenic molecules is increased and the production of angiogenic inhibitors is suppressed, leading to an "angiogenic switch". Here we present an overview of the role of angiogenesis in multiple myeloma, the pro-angiogenic factors produced by myeloma cells and the microenvironment, and the mechanisms involved in the myeloma-induced angiogenic switch. Current data suggest that the increased bone marrow angiogenesis in multiple myeloma is due to the aberrant expression of angiogenic factors by myeloma cells, the subsequent increase in pro-angiogenic activity of normal plasma cells as a result of myeloma cell angiogenic activity, and the increased number of plasma cells overall. Hypoxia also contributes to the angiogenic properties of the myeloma marrow microenvironment. The transcription factor hypoxia-inducible factor-1α is overexpressed by myeloma cells and affects their transcriptional and angiogenic profiles. In addition, potential roles of the tumor suppressor gene inhibitor of growth family member 4 and homeobox B7 have also been recently highlighted as repressors of angiogenesis and pro-angiogenic related genes, respectively. This complex pathogenetic model of myeloma-induced angiogenesis suggests that several proangiogenic molecules and related genes in myeloma cells and the microenvironment are potential therapeutic targets.

show abstract

The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis

Cited by 649 publications

References 91 publications

Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression

Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression

Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival

Angiogenesis and Multiple Myeloma

Contact Info

Product

Resources

About